A61K 31/522
Having oxo groups directly attached to the heterocyclic ring
Official title: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K31/522 (Having oxo groups directly attached to the heterocyclic ring) appears on 1,889 US grants and 3,945 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,889
- Published applications
- 3,945
- Assignees
- 1,640
- Inventors
- 6,341
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 6 | 0 |
| 1996 | 13 | 0 |
| 1997 | 28 | 0 |
| 1998 | 34 | 0 |
| 1999 | 39 | 0 |
| 2000 | 34 | 0 |
| 2001 | 35 | 12 |
| 2002 | 47 | 64 |
| 2003 | 42 | 93 |
| 2004 | 21 | 95 |
| 2005 | 27 | 129 |
| 2006 | 40 | 154 |
| 2007 | 14 | 146 |
| 2008 | 24 | 107 |
| 2009 | 37 | 104 |
| 2010 | 55 | 106 |
| 2011 | 36 | 125 |
| 2012 | 61 | 129 |
| 2013 | 75 | 158 |
| 2014 | 75 | 188 |
| 2015 | 101 | 201 |
| 2016 | 93 | 206 |
| 2017 | 102 | 197 |
| 2018 | 103 | 169 |
| 2019 | 112 | 201 |
| 2020 | 92 | 177 |
| 2021 | 106 | 218 |
| 2022 | 89 | 236 |
| 2023 | 86 | 196 |
| 2024 | 100 | 210 |
| 2025 | 94 | 157 |
| 2026 | 62 | 167 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of treating fibrotic liver diseases or conditions with indeglitazar29 Sep 2026US 12,746,225 B2Pleiogenix Inc.
- Methods of treating Prader Willi Syndrome and conditions associated with low basal metabolic rate or hyperphagia using a KATP channel opener29 Sep 2026US 12,746,244 B2Sedogen LLC
- Methods and compositions for delivery of agents across the blood-brain barrier29 Sep 2026US 12,747,269 B2The Brigham and Women S Hospital, Inc.
- Histone deacetylase inhibitors for use in immunotherapy22 Sep 2026US 12,740,986 B2Viracta Subsidiary, Inc.
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- Tea compositions comprising paraxanthine and methods of production thereof8 Oct 2026US 2026/0305643 A1
- Methods of preventing post-traumatic osteoarthritis using metformin8 Oct 2026US 2026/0306428 A1
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Paraxanthine-based bioactive composition and method of use thereof8 Oct 2026US 2026/0306499 A1Px Ing, LLC
- Compositions and methods using thymol and/or carvacrol for induction of autophagy1 Oct 2026US 2026/0294840 A1Societe des Produits Nestle S. A.
Most cited
By later US patents
- Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine486US 10,299,720 B2The General Hospital Corporation · 2019
- Controlled-release formulations coated with aqueous dispersions of ethylcellulose445US 5,472,712 AEuroceltique, S.A. · 1995
- Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer438US 5,273,760 AEuroceltigue, S.A. · 1993
- Orally administrable opioid formulations having extended duration of effect437US 5,968,551 APurdue Pharma L. P. · 1999
- Method of treating humans with opioid formulations having extended controlled release300US 6,143,322 APurdue Pharma L. P. · 2000